Predictive Oncology Stock Price, News & Analysis

Predictive Oncology Inc. (NASDAQ: POAI), which is changing its corporate name to Axe Compute Inc. effective December 11, 2025, is a company that combines artificial intelligence, machine learning, and a large biobank of human tumor samples to support early-stage oncologic drug discovery, drug development, and drug repurposing. The company is headquartered in Pittsburgh, Pennsylvania and its common stock trades on the Nasdaq Capital Market under the ticker symbol POAI, with a transition to the symbol AGPU expected to occur on or about December 12, 2025.

According to multiple company disclosures, Predictive Oncology focuses on using AI and machine learning to help identify which drug compounds are most likely to be effective against specific tumor samples. Its scientifically validated AI platform, known as PEDAL, is described as being able to predict with high accuracy whether a tumor sample will respond to a particular drug compound. This is intended to support more informed selection of drug and tumor-type combinations for subsequent in‑vitro testing and to enable partners to prioritize promising candidates earlier in the discovery and development process.

A central asset for Predictive Oncology is its biobank of more than 150,000 assay‑capable heterogeneous human tumor samples. Company materials state that these samples span a large number of cancer types and have been used to generate extensive drug response data over many years. This biobank underpins the company’s AI models, supports high‑throughput screening approaches, and is used in collaborations that aim to identify new indications for existing drugs, including drug repurposing efforts with external partners.

AI‑driven drug discovery and development

Predictive Oncology describes itself as being on the cutting edge of the use of artificial intelligence and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients. Its PEDAL platform uses data derived from wet‑lab testing of human tumor samples to train models that can predict tumor response to drug compounds. Company communications highlight applications in drug discovery, biomarker discovery, and drug repurposing, as well as potential use of AI‑powered multi‑omic models to predict survival outcomes in specific cancers.

The company reports that it has developed AI‑powered machine learning models that incorporate patient and tumor heterogeneity into early discovery work. These capabilities have been applied, for example, to ovarian cancer, where the company states it has built models that predict short‑ and long‑term survival outcomes and has identified novel biomarkers linked to survival and drug response using deep learning methods. Predictive Oncology positions these models as tools that can support both research and, potentially, clinical decision‑making.

Biobank, CLIA laboratory, and tumor profiling

Predictive Oncology’s operations are supported by a wholly owned CLIA‑certified laboratory facility, which is used to perform assays on patient‑derived tumor samples. The company emphasizes that its biobank and lab infrastructure allow it to generate high‑quality data on tumor growth and drug response, including the transition from two‑dimensional cell culture to three‑dimensional cell spheroids and cryopreserved dissociated tumor cells.

A key commercial and scientific asset highlighted by the company is ChemoFx, a live‑cell tumor profiling assay that uses a patient’s own cancer cells to measure chemotherapy responses in vitro. Company materials explain that ChemoFx tests multiple chemotherapies on a patient’s tumor cells before treatment selection, with the goal of indicating which chemotherapies are more likely to be effective and which are less likely to provide benefit. Predictive Oncology describes ChemoFx as a flagship assay that has been used to populate its tumor biobank and generate drug response data over many years, particularly in ovarian and other gynecologic cancers, with potential extension to additional tumor types.

Drug repurposing and collaborations

Beyond de novo discovery, Predictive Oncology is active in drug repurposing. The company reports that it uses its AI and machine learning capabilities, together with its tumor biobank, to screen existing or previously abandoned drug candidates for potential new cancer indications. For example, it has described work using publicly available datasets on drugs that were discontinued by large pharmaceutical companies to identify compounds that may warrant further exploration in colon and breast tumor indications.

The company also engages in collaborations with external organizations. One highlighted relationship is a strategic collaboration with Every Cure, a nonprofit focused on identifying new uses for existing drugs. Under this collaboration, Predictive Oncology provides data generated from pairing patient tumor samples with a large set of FDA‑approved drugs, supporting Every Cure’s AI‑driven efforts to prioritize repurposing opportunities. Predictive Oncology positions this as aligned with its broader goal of enabling drug developers and partners to expand and replenish their pipelines through data‑driven insights.

Digital asset treasury and Strategic Compute Reserve

In addition to its oncology‑focused activities, Predictive Oncology has expanded its business to include a digital asset treasury strategy centered on ATH, the native utility token of the Aethir network. Company news releases and SEC filings describe private placement transactions through which Predictive Oncology received cash proceeds and in‑kind contributions of ATH tokens. The company states that it intends to use ATH holdings to implement a digital asset treasury strategy and to operate on the Aethir ecosystem.

Predictive Oncology characterizes this strategy as creating a Strategic Compute Reserve. Through its ATH holdings, the company expects to function as an operator on the Aethir network, which is described as a decentralized GPU infrastructure platform designed to provide AI‑related compute resources. Company statements indicate that this role is intended to support Aethir’s ability to provide a global infrastructure layer for AI and to "democratize" access to AI infrastructure, while also giving Predictive Oncology a new line of business in active digital asset management focused on AI compute.

Capital markets, listing status, and corporate evolution

Predictive Oncology’s common stock is listed on the Nasdaq Capital Market. The company has reported actions to address Nasdaq listing requirements, including a 1‑for‑15 reverse stock split of its common stock that became effective on September 30, 2025. Company disclosures state that this reverse split was primarily intended to help satisfy Nasdaq’s minimum bid price requirement.

In December 2025, the company filed a Certificate of Amendment to change its corporate name from Predictive Oncology Inc. to Axe Compute Inc., effective December 11, 2025. In connection with this name change, Nasdaq is expected to change the company’s ticker symbol from POAI to AGPU on or about December 12, 2025. SEC filings note that outstanding stock certificates remain valid and that no change will be made to the CUSIP number in connection with the name change.

The company has also disclosed various capital raising and financing arrangements, including private placements involving cash and digital assets, an at‑the‑market offering program, and a standby equity purchase agreement. These activities are described in SEC filings and news releases as supporting both its AI‑driven oncology business and its digital asset treasury strategy.

Business focus and sector classification

Based on the information provided, Predictive Oncology operates at the intersection of AI‑enabled drug discovery, oncology diagnostics and tumor profiling, and digital asset‑supported AI infrastructure. While the industry classification referenced is surgical and medical instrument manufacturing, the company’s own descriptions emphasize its role as a science‑driven, AI‑focused enterprise that uses a CLIA laboratory, a large tumor biobank, and computational platforms to support pharmaceutical and biotech partners, academic collaborators, and other stakeholders engaged in cancer research and development.

Investors and researchers examining POAI (and, following the name and ticker change, AGPU) can use this overview as a starting point to understand the company’s combination of oncology‑focused AI platforms, laboratory and biobank assets, drug repurposing initiatives, and its newer digital asset treasury strategy linked to AI compute infrastructure.